JNJ · Company research
Johnson & Johnson (JNJ): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
80records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| GSK's New Drugs and Pipeline Hold the Key to Long-Term Growth | GSK is focusing on newer specialty medicines and vaccines to offset pressure from older products and drive long-term growth. Recent product launches including Blenrep, Jemperli, and Arexvy are expected to become major revenue contributors, with Blenrep anticipated as a key growth driver over 3-4 years. The company has doubled its phase II and III blockbuster-potential assets since 2022 and expects sales exceeding £40 billion by 2031. However, GSK faces significant competition from major pharmaceutical companies and must navigate patent expirations, particularly in HIV. | View source ↗ | Zacks Investment Research | Oct 20, 2026 | neutral | 0.111 | 1 |
| Mestag Therapeutics Appoints Philip Astley-Sparke and Victor Sandor, M.D.C.M., to its Board of Directors | Mestag Therapeutics announced the appointment of Philip Astley-Sparke and Victor Sandor, M.D.C.M. to its Board of Directors. Both appointees bring extensive biotech and oncology development experience. The appointments strengthen the Board as Mestag advances MST-0312, a targeted lymphotoxin-beta agonist bispecific antibody, in the Phase 1 STARLYS trial for patients with advanced solid tumors. | View source ↗ | GlobeNewswire Inc. | Oct 20, 2026 | bullish | 0.5 | 1 |
| 2 Industries Beyond AI With Long-Term Demand Drivers for 2027 | As AI dominates investment focus, healthcare and waste management sectors offer alternative diversification opportunities. Healthcare benefits from an aging population and rising medical needs, while waste management provides recurring revenue from essential services. Key companies like Abbott, Johnson & Johnson, Stryker, Waste Management, and Republic Services are positioned to capitalize on these structural trends. | View source ↗ | Zacks Investment Research | Oct 19, 2026 | bullish | 1 | 1 |
| 3 Wall Street Analysts See Intuitive Surgical Hitting $500. Here's the Bull Case. | Three Wall Street analysts have $500 price targets for Intuitive Surgical, citing strong growth in robot-assisted surgery procedures and the rollout of the da Vinci 5 platform. The company benefits from a recurring revenue model through instruments and accessories, with procedures growing 15% year-over-year. However, the stock's high P/E ratio of ~49 leaves limited room for disappointment. | View source ↗ | The Motley Fool | Oct 19, 2026 | bullish | 0.333 | 1 |
| Stryker Enters Soft-Tissue Robotics With $400 Million CMR Deal | Stryker announced a $400 million preferred equity investment in CMR Surgical, gaining exclusive U.S. sales rights for the Versius robotic surgery platform and an option to acquire the company. The deal allows Stryker to expand into soft-tissue robotics, complementing its existing Mako orthopedic platform, while CMR Surgical retains global commercialization rights outside the U.S. | View source ↗ | Zacks Investment Research | Oct 19, 2026 | bullish | 0.25 | 1 |
| AbbVie's Neuroscience Franchise: What to Expect Ahead of Q3 Results | AbbVie's neuroscience revenues are projected to reach $3.29 billion in Q3 2026, representing approximately 16% year-over-year growth. Key contributors include established drugs Vraylar ($1.08B) and Botox Therapeutic ($1.07B), along with newer products like Vyalev ($283M) and the recently FDA-approved Juvmo. The company faces competition from Biogen and Johnson & Johnson in the neuroscience market. | View source ↗ | Zacks Investment Research | Oct 19, 2026 | bullish | 0.333 | 1 |
| Zacks Investment Ideas feature highlights: Intuitive Surgical | Intuitive Surgical (ISRG), the leader in surgical robotics, has fallen 30% from early 2025 highs but presents a strong buy opportunity with ~40% upside potential. The company demonstrates impressive fundamentals including double-digit earnings and revenue growth, a debt-free balance sheet, and strong free cash flow expansion. ISRG earned a Zacks Rank #2 (Buy) rating and is positioned for a technical breakout ahead of Q3 earnings. | View source ↗ | Zacks Investment Research | Oct 19, 2026 | bullish | 0.333 | 1 |
| Should You Invest in This Dividend King on the Dip? | Johnson & Johnson reported strong Q3 results with revenue beating expectations and raised full-year guidance, driven by excellent pharmaceutical segment performance including cancer drug Darzalex and autoimmune treatment Tremfya. However, the medtech division underperformed, particularly due to safety concerns with Impella heart pumps. Despite near-term headwinds, the article argues J&J remains a solid long-term buy given its robust pharmaceutical pipeline, upcoming medtech innovations like robotic surgery devices, and its status as a Dividend King with 64 consecutive years of dividend increases. | View source ↗ | The Motley Fool | Oct 17, 2026 | bullish | 1 | 1 |
| Johnson & Johnson Just Raised Its Sales Outlook Again. Here's Why the Dividend King Is Still a Buy. | Johnson & Johnson raised its full-year sales and earnings guidance after beating Q3 estimates, but the stock fell 6% due to disappointing medical device sales. Despite near-term concerns about the MedTech division and a planned DePuy Synthes spinoff, the company's strong oncology business growth (16%+ in Q3) and reliable 64-year dividend streak make it an attractive long-term buy at current valuations. | View source ↗ | The Motley Fool | Oct 17, 2026 | bullish | 1 | 1 |
| Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? | The article compares Bristol-Myers Squibb and Johnson & Johnson as healthcare investment options. BMY trades at a cheaper valuation (9.3x forward P/E vs JNJ's 21x) with a higher dividend yield of 4.16%, but faces patent cliffs and pricing pressures. JNJ offers greater revenue scale ($94.2B vs $48.2B), diversified business segments, and a 64-year dividend growth streak, making it the recommended choice for 2026 despite its premium valuation. | View source ↗ | The Motley Fool | Oct 17, 2026 | bullish | 0.167 | 1 |
| Forget AI Stocks: Buy Med-Tech Stock ISRG Now for 40% Upside | Intuitive Surgical, the leader in surgical robotics, has fallen 30% from early 2025 highs but is poised for a technical breakout ahead of its Q3 earnings release on October 20. With strong fundamentals including double-digit earnings and revenue growth, a debt-free balance sheet, and ~43% upside potential to all-time highs, the stock earns a Zacks Rank #2 (Buy) rating. The company projects 15% Q3 revenue growth and 17% revenue growth for 2026. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 0.333 | 1 |
| Johnson & Johnson: 3 Key Takeaways for Long-Term Investors | Johnson & Johnson raised its full-year sales outlook after Q3 2026 operational revenue grew 6%, putting the company on track to exceed $100 billion in annual revenue for the first time. Strong pharmaceutical demand, particularly in cancer treatments, drove performance. However, the medical device segment faced headwinds with only 2.5% growth due to Middle East disruptions and China's bulk-buying program. Management plans to restore momentum through new product launches and is leaning toward spinning off its DePuy Synthes orthopedics subsidiary by mid-2027. | View source ↗ | The Motley Fool | Oct 16, 2026 | bullish | 0.5 | 1 |
| Johnson & Johnson: 3 Key Takeaways for Long-Term Investors | Johnson & Johnson raised its full-year sales outlook after Q3 2026 operational revenue grew 6%, putting the company on track to exceed $100 billion in annual revenue for the first time. Strong pharmaceutical demand, particularly in cancer treatments, drove performance. However, the medical device segment faced headwinds with only 2.5% growth due to Middle East disruptions and China's bulk-buying program. Management plans to restore momentum through new product launches and is leaning toward spinning off its DePuy Synthes orthopedics subsidiary by mid-2027. | View source ↗ | The Motley Fool | Oct 16, 2026 | bullish | 0.5 | 1 |
| This Unstoppable Vanguard ETF Could Turn $500 Per Month Into $1 Million Over the Long Term | The Vanguard S&P 500 Growth ETF (VOOG) tracks the S&P 500 Growth index of 151 best-performing growth stocks, heavily weighted toward AI and technology companies. With a 16.9% compound annual return since 2010 and 28.4% over the last three years, consistent $500 monthly investments could potentially reach $1 million in approximately 23 years, even at conservative 14.1% annual returns. | View source ↗ | The Motley Fool | Oct 16, 2026 | bullish | 0.538 | 1 |
| This Unstoppable Vanguard ETF Could Turn $500 Per Month Into $1 Million Over the Long Term | The Vanguard S&P 500 Growth ETF (VOOG) tracks the S&P 500 Growth index of 151 best-performing growth stocks, heavily weighted toward AI and technology companies. With a 16.9% compound annual return since 2010 and 28.4% over the last three years, consistent $500 monthly investments could potentially reach $1 million in approximately 23 years, even at conservative 14.1% annual returns. | View source ↗ | The Motley Fool | Oct 16, 2026 | bullish | 0.538 | 1 |
| Breakfast News: Week in Review | Tech stocks faced headwinds this week as inflation concerns and rising bond yields pressured AI-related companies like Nvidia and Broadcom. CoreWeave's debt spike to $52 billion with 15% bond yields reignited AI debt bubble fears. Despite strong earnings, TSMC, Johnson & Johnson, and Morgan Stanley all sold off, while JPMorgan rallied on solid lending metrics. Consumer spending signals remain mixed, with JPMorgan seeing strength but Domino's warning of economic headwinds. Rocket Lab delayed Neutron's first flight to 2027 due to manufacturing issues. Valuation concerns persist across tech, with ASML, Atlassian, and Klarna highlighting the importance of entry price. | View source ↗ | The Motley Fool | Oct 16, 2026 | bearish | -0.242 | 1 |
| Breakfast News: Week in Review | Tech stocks faced headwinds this week as inflation concerns and rising bond yields pressured AI-related companies like Nvidia and Broadcom. CoreWeave's debt spike to $52 billion with 15% bond yields reignited AI debt bubble fears. Despite strong earnings, TSMC, Johnson & Johnson, and Morgan Stanley all sold off, while JPMorgan rallied on solid lending metrics. Consumer spending signals remain mixed, with JPMorgan seeing strength but Domino's warning of economic headwinds. Rocket Lab delayed Neutron's first flight to 2027 due to manufacturing issues. Valuation concerns persist across tech, with ASML, Atlassian, and Klarna highlighting the importance of entry price. | View source ↗ | The Motley Fool | Oct 16, 2026 | bearish | -0.242 | 1 |
| Breaking Down The Big 3 Investing Strategies | The article explains three primary investment strategies: income investing focuses on dividend-paying stocks and regular payouts; growth investing targets companies with above-average earnings and revenue growth, often at premium valuations; and value investing seeks undervalued stocks trading below their intrinsic value. Each strategy caters to different investor profiles and risk tolerances. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 1 | 1 |
| Breaking Down The Big 3 Investing Strategies | The article explains three primary investment strategies: income investing focuses on dividend-paying stocks and regular payouts; growth investing targets companies with above-average earnings and revenue growth, often at premium valuations; and value investing seeks undervalued stocks trading below their intrinsic value. Each strategy caters to different investor profiles and risk tolerances. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 1 | 1 |
| 3 Companies Raising Guidance This Earnings Season | BWX Technologies, Johnson & Johnson, and UnitedHealth Group have all raised their FY26 outlooks following solid quarterly earnings. BWX Technologies saw strong commercial nuclear operations growth, J&J benefited from pharmaceutical portfolio strength, and UnitedHealth Group showed improving cost trends with a lower medical care ratio. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 1 | 1 |
| 3 Companies Raising Guidance This Earnings Season | BWX Technologies, Johnson & Johnson, and UnitedHealth Group have all raised their FY26 outlooks following solid quarterly earnings. BWX Technologies saw strong commercial nuclear operations growth, J&J benefited from pharmaceutical portfolio strength, and UnitedHealth Group showed improving cost trends with a lower medical care ratio. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 1 | 1 |
| XENE's Depression Trial Setback: Is Its Pipeline Still Attractive? | Xenon Pharmaceuticals paused enrollment in phase III depression trials for azetukalner after unexpected neurological and psychiatric side effects emerged, including confusion, speech difficulties, and psychosis cases. The company is reviewing dose adjustments with top-line results expected in Q1 2027. However, Xenon's epilepsy program remains promising, with an FDA application pending for focal onset seizures treatment, offering potential growth opportunities despite the depression program setback. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bearish | -0.333 | 1 |
| XENE's Depression Trial Setback: Is Its Pipeline Still Attractive? | Xenon Pharmaceuticals paused enrollment in phase III depression trials for azetukalner after unexpected neurological and psychiatric side effects emerged, including confusion, speech difficulties, and psychosis cases. The company is reviewing dose adjustments with top-line results expected in Q1 2027. However, Xenon's epilepsy program remains promising, with an FDA application pending for focal onset seizures treatment, offering potential growth opportunities despite the depression program setback. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bearish | -0.333 | 1 |
| Where Could Johnson & Johnson’s Next Growth Come From? - Trefis | Where Could Johnson & Johnson’s Next Growth Come From? Trefis | View source ↗ | Trefis | Oct 15, 2026 | neutral | 0 | 0.6 |
| Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today | A $1,000 investment in Halozyme Therapeutics (HALO) made in October 2016 would be worth $11,612.33 as of October 15, 2026, representing a 1,061.23% gain. This significantly outperformed the S&P 500's 261.89% return over the same period. The biopharmaceutical company's success is driven by royalties from its ENHANZE drug delivery technology licensed to major pharma partners, though it faces headwinds from biosimilar competition on blockbuster drugs. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | neutral | 0.111 | 1 |
| Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today | A $1,000 investment in Halozyme Therapeutics (HALO) made in October 2016 would be worth $11,612.33 as of October 15, 2026, representing a 1,061.23% gain. This significantly outperformed the S&P 500's 261.89% return over the same period. The biopharmaceutical company's success is driven by royalties from its ENHANZE drug delivery technology licensed to major pharma partners, though it faces headwinds from biosimilar competition on blockbuster drugs. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | neutral | 0.111 | 1 |
| Johnson & Johnson (JNJ) Stock Rebounds While Earnings Power Keeps Eroding - Simply Wall Street | Johnson & Johnson (JNJ) Stock Rebounds While Earnings Power Keeps Eroding Simply Wall Street | View source ↗ | Simply Wall Street | Oct 15, 2026 | neutral | 0 | 0.6 |
| These Analysts Cut Their Forecasts On Johnson & Johnson After Q3 Results - Benzinga | These Analysts Cut Their Forecasts On Johnson & Johnson After Q3 Results Benzinga | View source ↗ | Benzinga | Oct 14, 2026 | neutral | 0 | 0.6 |
| Which Pharma Stock Looks More Attractive: Sanofi or AbbVie? | Sanofi and AbbVie are compared as major pharmaceutical companies with different growth drivers. Sanofi, powered by Dupixent's strong performance and newer medicines, trades at a lower valuation (7.82x forward earnings) with a 4.5% dividend yield, while AbbVie relies on Skyrizi and Rinvoq to offset Humira's decline but trades at 19.62x forward earnings with a 2.5% yield. Analysts favor Sanofi (Zacks Rank #3 Hold) over AbbVie (Rank #4 Sell) due to its attractive valuation and upgraded growth outlook. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | neutral | 0 | 1 |
| Why Did J&J Stock Fall After Q3 Earnings Despite Raised Guidance? | Johnson & Johnson's shares fell 5.8% after Q3 2026 results showed earnings beat but sales missed expectations. MedTech segment underperformed with only 2.5% growth due to Abiomed declines and international market challenges, while Innovative Medicine remained strong. Despite headwinds, J&J raised full-year guidance and targets over $100 billion in 2026 revenue with accelerated growth expected in 2027. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bearish | -0.2 | 1 |
| Why Did J&J Stock Fall After Q3 Earnings Despite Raised Guidance? | Johnson & Johnson's shares fell 5.8% after Q3 2026 results showed earnings beat but sales missed expectations. MedTech segment underperformed with only 2.5% growth due to Abiomed declines and international market challenges, while Innovative Medicine remained strong. Despite headwinds, J&J raised full-year guidance and targets over $100 billion in 2026 revenue with accelerated growth expected in 2027. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bearish | -0.2 | 1 |
| J&J Beat and Raised. The Stock Fell Anyway. Here’s What the Target Says - 24/7 Wall St. | J&J Beat and Raised. The Stock Fell Anyway. Here’s What the Target Says 24/7 Wall St. | View source ↗ | 24/7 Wall St. | Oct 14, 2026 | neutral | 0 | 0.6 |
| JNJ Q3 Earnings Call Highlights Growth Outlook and MedTech Challenges | Johnson & Johnson raised its 2026 sales guidance to $101-$101.4 billion and adjusted EPS to $11.05-$11.15, driven by strong Innovative Medicine growth of 7.9%, particularly from TREMFYA (up 68.3%) and DARZALEX (up 15.4%). However, MedTech underperformed with only 2.5% growth due to competitive pressures and international headwinds. The company expects $1.36 per share in acquisition-related earnings in 2027 and targets double-digit growth by decade-end. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | neutral | 0 | 1 |
| JNJ Q3 Earnings Call Highlights Growth Outlook and MedTech Challenges | Johnson & Johnson raised its 2026 sales guidance to $101-$101.4 billion and adjusted EPS to $11.05-$11.15, driven by strong Innovative Medicine growth of 7.9%, particularly from TREMFYA (up 68.3%) and DARZALEX (up 15.4%). However, MedTech underperformed with only 2.5% growth due to competitive pressures and international headwinds. The company expects $1.36 per share in acquisition-related earnings in 2027 and targets double-digit growth by decade-end. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | neutral | 0 | 1 |
| UnitedHealth vs. Johnson & Johnson: Which Stock Is the Better Buy After Q3 Earnings? | UnitedHealth and Johnson & Johnson both raised full-year guidance after Q3 earnings, but with contrasting performance. UnitedHealth beat expectations with 60% YoY EPS growth driven by improved medical cost management, while J&J saw earnings decline 7.5% YoY despite pharmaceutical growth offsetting weak MedTech performance. UnitedHealth is recommended as the better buy due to stronger earnings momentum, lower valuation (19X vs 23X forward earnings), and higher dividend yield (2.45% vs 2%). | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.5 | 1 |
| UnitedHealth vs. Johnson & Johnson: Which Stock Is the Better Buy After Q3 Earnings? | UnitedHealth and Johnson & Johnson both raised full-year guidance after Q3 earnings, but with contrasting performance. UnitedHealth beat expectations with 60% YoY EPS growth driven by improved medical cost management, while J&J saw earnings decline 7.5% YoY despite pharmaceutical growth offsetting weak MedTech performance. UnitedHealth is recommended as the better buy due to stronger earnings momentum, lower valuation (19X vs 23X forward earnings), and higher dividend yield (2.45% vs 2%). | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.5 | 1 |
| Health Bellwether J&J Slumps As Middle East Conflict Hampers Medtech Sales - Investor's Business Daily | Health Bellwether J&J Slumps As Middle East Conflict Hampers Medtech Sales Investor's Business Daily | View source ↗ | Investor's Business Daily | Oct 13, 2026 | neutral | 0 | 0.6 |
| Why Johnson & Johnson Stock Dropped Today - The Motley Fool | Why Johnson & Johnson Stock Dropped Today The Motley Fool | View source ↗ | The Motley Fool | Oct 13, 2026 | neutral | 0 | 0.6 |
| Johnson & Johnson stock falls despite strong earnings as investors focus on medtech unit - Yahoo Finance | Johnson & Johnson stock falls despite strong earnings as investors focus on medtech unit Yahoo Finance | View source ↗ | Yahoo Finance | Oct 13, 2026 | neutral | 0 | 0.6 |
| Stock Market Midday, Oct. 13: Bank Earnings and Chip Pressure Drive Mixed Trading | Major stock indexes traded mixed on October 13, 2026, as bank earnings kicked off the season with varied results and semiconductor stocks faced significant selling pressure. The S&P 500 fell 0.25%, the Nasdaq dropped 0.37%, and the Dow declined 0.18%. Goldman Sachs gained on strong earnings, while Wells Fargo and Johnson & Johnson declined on disappointing results. Semiconductor stocks, particularly Micron Technology, slid over 5% amid intensifying global competition and Chinese chip innovations. | View source ↗ | The Motley Fool | Oct 13, 2026 | bearish | -0.192 | 1 |
| Stock Market Midday, Oct. 13: Bank Earnings and Chip Pressure Drive Mixed Trading | Major stock indexes traded mixed on October 13, 2026, as bank earnings kicked off the season with varied results and semiconductor stocks faced significant selling pressure. The S&P 500 fell 0.25%, the Nasdaq dropped 0.37%, and the Dow declined 0.18%. Goldman Sachs gained on strong earnings, while Wells Fargo and Johnson & Johnson declined on disappointing results. Semiconductor stocks, particularly Micron Technology, slid over 5% amid intensifying global competition and Chinese chip innovations. | View source ↗ | The Motley Fool | Oct 13, 2026 | bearish | -0.192 | 1 |
| Biggest stock movers Tuesday: SIX, MU, JNJ, and more - Seeking Alpha | Biggest stock movers Tuesday: SIX, MU, JNJ, and more Seeking Alpha | View source ↗ | Seeking Alpha | Oct 13, 2026 | neutral | 0 | 0.6 |
| Small-Business Optimism Dips in September | Pre-market futures showed mixed signals as investors paused on AI stocks, with the Dow up 420 points while the Nasdaq fell 217 points. Oil prices dropped 1.5% amid Middle East tensions, and bond yields declined. Small business optimism dipped for the second consecutive month in September. Major financial institutions reported Q3 earnings with mixed results: JPMorgan Chase missed estimates, Goldman Sachs significantly beat expectations, Wells Fargo delivered mixed results, and Johnson & Johnson beat on earnings but missed slightly on revenue. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bearish | -0.571 | 1 |
| Small-Business Optimism Dips in September | Pre-market futures showed mixed signals as investors paused on AI stocks, with the Dow up 420 points while the Nasdaq fell 217 points. Oil prices dropped 1.5% amid Middle East tensions, and bond yields declined. Small business optimism dipped for the second consecutive month in September. Major financial institutions reported Q3 earnings with mixed results: JPMorgan Chase missed estimates, Goldman Sachs significantly beat expectations, Wells Fargo delivered mixed results, and Johnson & Johnson beat on earnings but missed slightly on revenue. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bearish | -0.571 | 1 |
| J&J Q3 Earnings Beat Estimates, Sales Miss, View Raised, Stock Down | Johnson & Johnson reported Q3 2026 adjusted earnings of $2.59 per share, beating estimates, but sales of $25.4 billion missed expectations. Innovative Medicine sales grew 7.7% driven by Tremfya and newer therapies, while Stelara faced significant biosimilar competition. MedTech underperformed with a 2.5% increase missing estimates. J&J raised 2026 guidance but shares declined 2% in pre-market trading due to weaker-than-expected MedTech results. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.75 | 1 |
| J&J Q3 Earnings Beat Estimates, Sales Miss, View Raised, Stock Down | Johnson & Johnson reported Q3 2026 adjusted earnings of $2.59 per share, beating estimates, but sales of $25.4 billion missed expectations. Innovative Medicine sales grew 7.7% driven by Tremfya and newer therapies, while Stelara faced significant biosimilar competition. MedTech underperformed with a 2.5% increase missing estimates. J&J raised 2026 guidance but shares declined 2% in pre-market trading due to weaker-than-expected MedTech results. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.75 | 1 |
| Mixed Pre-Markets Greet Fresh Q3 Earnings Reports | Pre-market futures showed mixed signals on October 13, 2026, with the Dow up 420 points while the Nasdaq fell 217 points. Small-business optimism declined for the second consecutive month to 97.9 in September. Major financial institutions reported Q3 earnings with mixed results: JPMorgan Chase missed estimates on both earnings and revenue, Goldman Sachs significantly beat expectations, Wells Fargo delivered mixed results with earnings beating but revenues missing, and Johnson & Johnson beat on earnings but narrowly missed on revenue. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bearish | -0.571 | 1 |
| Mixed Pre-Markets Greet Fresh Q3 Earnings Reports | Pre-market futures showed mixed signals on October 13, 2026, with the Dow up 420 points while the Nasdaq fell 217 points. Small-business optimism declined for the second consecutive month to 97.9 in September. Major financial institutions reported Q3 earnings with mixed results: JPMorgan Chase missed estimates on both earnings and revenue, Goldman Sachs significantly beat expectations, Wells Fargo delivered mixed results with earnings beating but revenues missing, and Johnson & Johnson beat on earnings but narrowly missed on revenue. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bearish | -0.571 | 1 |
| Johnson & Johnson Beats Third-Quarter Earnings Estimates and Raises 2026 Revenue and Profit Outlook - Yahoo Finance | Johnson & Johnson Beats Third-Quarter Earnings Estimates and Raises 2026 Revenue and Profit Outlook Yahoo Finance | View source ↗ | Yahoo Finance | Oct 13, 2026 | neutral | 0 | 0.6 |
| Johnson & Johnson Stock Falls Despite Beating Q3 Expectations – Here’s Why - TipRanks | Johnson & Johnson Stock Falls Despite Beating Q3 Expectations – Here’s Why TipRanks | View source ↗ | TipRanks | Oct 13, 2026 | neutral | 0 | 0.6 |
| J&J posts weak medical device sales, shares fall - CNBC | J&J posts weak medical device sales, shares fall CNBC | View source ↗ | CNBC | Oct 13, 2026 | neutral | 0 | 0.6 |
| Johnson & Johnson (JNJ) Q3 Earnings Surpass Estimates | Johnson & Johnson reported Q3 2026 earnings of $2.59 per share, beating consensus estimates of $2.53, though revenues slightly missed expectations at $25.4 billion. Despite outperforming the S&P 500 by 27.4% year-to-date, the company received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revision trends, suggesting near-term underperformance. The Large Cap Pharmaceuticals industry ranks in the bottom 16% of sectors. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bearish | -1 | 1 |
| Johnson & Johnson (JNJ) Q3 Earnings Surpass Estimates | Johnson & Johnson reported Q3 2026 earnings of $2.59 per share, beating consensus estimates of $2.53, though revenues slightly missed expectations at $25.4 billion. Despite outperforming the S&P 500 by 27.4% year-to-date, the company received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revision trends, suggesting near-term underperformance. The Large Cap Pharmaceuticals industry ranks in the bottom 16% of sectors. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bearish | -1 | 1 |
| Want Passive Income for Life? Here Are 2 Dividend Stocks to Buy and Never Sell | The article recommends two Dividend King healthcare stocks for passive income: Abbott Laboratories and Johnson & Johnson. Both companies have demonstrated 50+ years of consecutive dividend increases, strong free cash flow, diversified business portfolios, and solid growth prospects. Abbott offers a 2.5% dividend yield with innovative products like the Libre Duo glucose monitor, while J&J pays a 2% yield and is positioned to reach $100 billion in annual revenue with a strong oncology pipeline. | View source ↗ | The Motley Fool | Oct 12, 2026 | bullish | 1 | 1 |
| Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026? | Abbott Laboratories and Intuitive Surgical represent different healthcare investment strategies. Abbott offers diversified operations across diagnostics, nutrition, and medical devices with a conservative 18x forward P/E ratio, $7.4B free cash flow, and 2.49% dividend yield. Intuitive Surgical commands a premium 39x P/E multiple but delivers 21% revenue growth, zero debt, and dominance in robotic-assisted surgery. Both companies project ~13% sales growth for 2026, but Abbott's lower valuation and new Cologuard cancer screening acquisition make it the better buy for long-term value investors. | View source ↗ | The Motley Fool | Oct 12, 2026 | bullish | 0.25 | 1 |
| Middle East Tensions Rattle Markets | Markets face a volatile week with Middle East tensions following Houthi attacks on Saudi Arabia's airport, pushing oil prices higher. Key economic data including September CPI and PPI inflation reports are expected this week, with CPI anticipated to rise 30 basis points to +3.7%. Q3 earnings season kicks off with major banks and healthcare companies reporting, including JPMorgan, Citigroup, Wells Fargo, Goldman Sachs, Johnson & Johnson, and UnitedHealthcare. | View source ↗ | Zacks Investment Research | Oct 12, 2026 | neutral | 0.04 | 1 |
| Big Week of Data: Inflation & Q3 Earnings | Houthi attacks on Saudi Arabia's Riyadh airport over the weekend killed 14 and injured over 300, sending oil prices higher (WTI at $93/bbl, Brent at $106/bbl). The market faces a busy week with Q3 earnings from major banks and healthcare companies, alongside critical CPI and PPI inflation reports expected to show inflation ticking higher. | View source ↗ | Zacks Investment Research | Oct 12, 2026 | neutral | 0.04 | 1 |
| Here’s How Much Johnson & Johnson Stock Is Expected to Move After Earnings - Investopedia | Here’s How Much Johnson & Johnson Stock Is Expected to Move After Earnings Investopedia | View source ↗ | Investopedia | Oct 12, 2026 | neutral | 0 | 0.6 |
| How to Find Strong Medical Stocks Slated for Positive Earnings Surprises | The article explains how to identify stocks with positive earnings surprises using the Zacks Earnings ESP (Expected Surprise Prediction) filter, which compares the most recent analyst estimates against consensus estimates. The strategy combining positive ESP with Zacks Rank #3 or better has historically resulted in 70% positive earnings surprises and 28.3% average annual returns. Johnson & Johnson and Pfizer are highlighted as medical stocks with positive ESPs ahead of their upcoming earnings reports. | View source ↗ | Zacks Investment Research | Oct 12, 2026 | bullish | 1 | 1 |
| 2 Dividend Stocks Worth Holding Forever (Including 1 Dividend King) | Johnson & Johnson and Realty Income are recommended as long-term dividend stocks. J&J, a Dividend King with 64 consecutive years of dividend increases, offers defensive healthcare stability through its innovative medicine and medtech businesses. Realty Income, with 136 monthly dividend increases, provides predictable income through its diversified commercial real estate portfolio with strong occupancy and expansion into data centers and private capital partnerships. | View source ↗ | The Motley Fool | Oct 10, 2026 | bullish | 0.667 | 1 |
| Estimates Keep Rising as Q3 Earnings Season Takes Center Stage | Q3 earnings season begins with JPMorgan, Citigroup, and others reporting results. S&P 500 earnings are expected to grow 24.3% YoY with positive revisions across 7 of 16 sectors. However, banks face pressure from rising Treasury yields impacting net interest margins and deal flow. Of 19 companies that have reported, 78.9% beat EPS estimates, though results are heavily skewed by Micron's exceptional performance. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 0.222 | 1 |
| Cancer Stocks to Consider as Oncology Innovation Accelerates | The global oncology market is experiencing rapid growth due to rising cancer incidence, aging populations, and medical advances including immunotherapies, targeted medicines, and personalized vaccines. Major pharmaceutical companies are investing heavily in oncology R&D, with innovations in antibody-drug conjugates, bispecific antibodies, and next-generation immunotherapies. Three companies highlighted for oncology exposure are Pfizer, Merit Medical Systems, and Abbott Laboratories. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 1 | 1 |
| J&J Stock Ahead of Q3 Earnings: Should You Buy, Sell or Hold? | Johnson & Johnson will report Q3 2026 results on October 13 with consensus estimates for $25.37 billion in sales and $2.66 EPS. The company's Innovative Medicine segment is expected to drive growth through key drugs like Darzalex and new launches, but faces headwinds from Stelara biosimilar competition and upcoming patent expirations. Despite valuation concerns, analysts recommend staying invested given J&J's diversified business model, consistent growth trajectory, and pipeline strength. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 0.333 | 1 |
| Fund Update: 51,822 JOHNSON & JOHNSON (JNJ) shares added to SAPIENT CAPITAL LLC portfolio - Quiver Quantitative | Fund Update: 51,822 JOHNSON & JOHNSON (JNJ) shares added to SAPIENT CAPITAL LLC portfolio Quiver Quantitative | View source ↗ | Quiver Quantitative | Oct 8, 2026 | neutral | 0 | 0.6 |
| HALO Wins Court Order Blocking Merck's Keytruda SC in Europe | A Dutch patent court ruled that Merck's Keytruda subcutaneous formulation infringes Halozyme's MDASE patent, ordering Merck to cease manufacturing and sales across eight European markets. The ruling does not affect Keytruda's intravenous version. This marks another legal victory for Halozyme against Merck, though the company clarified that its separate ENHANZE technology and licensing business remain unaffected. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | neutral | 0 | 1 |
| Bayer Seeks Kerendia Label Expansion in Non-Diabetic CKD | Bayer announced FDA acceptance of a supplemental new drug application for Kerendia (finerenone) to treat chronic kidney disease in non-diabetic patients. The approval is based on positive phase III FIND-CKD trial data showing the drug significantly delayed kidney disease progression and reduced cardiovascular-kidney events. This expansion broadens Kerendia's addressable market and strengthens Bayer's cardiovascular and renal portfolio, with the drug already approved for diabetic CKD and heart failure in multiple markets. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.333 | 1 |
| Will Johnson & Johnson (JNJ) Beat Estimates Again in Its Next Earnings Report? | Johnson & Johnson is positioned to potentially beat earnings estimates in its upcoming October 13, 2026 report. The company has a track record of beating estimates with an average surprise of 1.62% over the past two quarters. With a positive Earnings ESP of +2.10% and a Zacks Rank #3 (Hold), the combination suggests a ~70% probability of beating consensus estimates. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 1 | 1 |
| Pfizer's Oncology Outlook: Key Drivers to Watch Ahead of Q3 Results | Pfizer's oncology revenues rose 3% to $4.17 billion in Q2 2026, representing 27% of total revenues. The company expects Q3 growth driven by newer drugs like Padcev, Lorbrena, and Braftovi-Mektovi, offset by declines in Ibrance and Adcetris. Pfizer is advancing the dual PD-1/VEGF inhibitor PF-08634404 across nine studies including two pivotal phase III trials. The stock trades at an attractive valuation with a Zacks Rank #2 (Buy) rating. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.667 | 1 |
| Prediction: Johnson & Johnson Will Be a Faster-Growing Company by 2030 Than Most Investors Expect | Johnson & Johnson is positioned for faster growth by 2030 following its separation from its slower-growing consumer health division. The company can now focus investments on its faster-growing biopharma and medtech segments. Key growth drivers include recent drug approvals like ICOTYDE and the FDA-cleared Ottava robotic surgery system, which operates in a market with significant expansion potential. Despite challenges from government price negotiations and talc-related lawsuits, J&J's diversified portfolio and strong dividend history make it an attractive long-term investment. | View source ↗ | The Motley Fool | Oct 8, 2026 | bullish | 0.5 | 1 |
| Which dow jones stocks are moving on Wednesday? - ChartMill | Which dow jones stocks are moving on Wednesday? ChartMill | View source ↗ | ChartMill | Oct 7, 2026 | neutral | 0 | 0.6 |
| Johnson & Johnson (JNJ): RBC Update & Stock Analysis - The Globe and Mail | Johnson & Johnson (JNJ): RBC Update & Stock Analysis The Globe and Mail | View source ↗ | The Globe and Mail | Oct 7, 2026 | neutral | 0 | 0.6 |
| JNJ Stock Advances After Hours On $5.5B Proposal To Resolve Talc Litigation - Stocktwits | JNJ Stock Advances After Hours On $5.5B Proposal To Resolve Talc Litigation Stocktwits | View source ↗ | Stocktwits | Oct 7, 2026 | neutral | 0 | 0.6 |
| PFE vs. JNJ: Which Stock Is the Better Value Option? - Yahoo Finance Singapore | PFE vs. JNJ: Which Stock Is the Better Value Option? Yahoo Finance Singapore | View source ↗ | Yahoo Finance Singapore | Oct 6, 2026 | neutral | 0 | 0.6 |
| Johnson & Johnson (JNJ) Earnings Expected to Grow: Should You Buy? - Yahoo Finance | Johnson & Johnson (JNJ) Earnings Expected to Grow: Should You Buy? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 6, 2026 | neutral | 0 | 0.6 |
| Johnson & Johnson (JNJ) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance | Johnson & Johnson (JNJ) Stock Drops Despite Market Gains: Important Facts to Note Yahoo Finance | View source ↗ | Yahoo Finance | Oct 5, 2026 | neutral | 0 | 0.6 |
| Was The Run In JNJ Stock Hiding In Plain Sight? - Trefis | Was The Run In JNJ Stock Hiding In Plain Sight? Trefis | View source ↗ | Trefis | Sep 30, 2026 | neutral | 0 | 0.6 |
| Johnson & Johnson (JNJ) Stock May Be Undervalued As Its 96% Run Continues - Yahoo Finance | Johnson & Johnson (JNJ) Stock May Be Undervalued As Its 96% Run Continues Yahoo Finance | View source ↗ | Yahoo Finance | Sep 29, 2026 | neutral | 0 | 0.6 |
| $85 Billion And Counting: JNJ Stock’s Steady Cash-Return Habit - Trefis | $85 Billion And Counting: JNJ Stock’s Steady Cash-Return Habit Trefis | View source ↗ | Trefis | Sep 28, 2026 | neutral | 0 | 0.6 |
| Why Is JNJ Stock Beating Rivals That Grow Faster? - Trefis | Why Is JNJ Stock Beating Rivals That Grow Faster? Trefis | View source ↗ | Trefis | Sep 22, 2026 | neutral | 0 | 0.6 |
| Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch. - The Motley Fool | Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch. The Motley Fool | View source ↗ | The Motley Fool | Aug 31, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.